One Down, Two To Go: Pfizer/BioNTech Booster Decision Creates Pressure For More Extra Shot Authorizations
Executive Summary
Inequity created by limiting the mRNA vaccine’s third dose to only those individuals who received a primary series of the same vaccine, as well as resulting operational complexities, warrant consideration of a mix-and-match approach with Moderna and J&J products, CDC advisors say; however, FDA appears most focused on vetting manufacturer-specific data on homologous boosting.
You may also be interested in...
Pfizer AdComm Asks Many Questions About COVID Vaccine For Ages 5-11, But Gets Few Answers
Often data was not available from FDA, CDC or the sponsor to answer subgroup, safety and other questions that could have influenced the outcome of the advisory committee meeting.
Full US FDA Independent Review Of Janssen Booster Data May Not Continue Post-EUA
The agency said its booster EUA decision was based on the immunogenicity studies that were submitted.
Coronavirus Update: Gates Foundation To Give $120m For Molnupiravir Access
The foundation is donating to help supply Merck/Ridgeback’s antiviral to low-income nations; also Pfizer got one step closer to full approval for booster shots of Comirnaty, while the FDA authorized Moderna and J&J boosters, and Daiichi Sankyo made progress on its own mRNA vaccine candidate. Shionogi's once-daily oral antiviral is also moving forward.